Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial

BACKGROUND. Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent activity and in combination with taxanes. We...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Prostate
Autores principales: Armstrong, Andrew J., Humeniuk, Michael S., Healy, Patrick, Szmulewitz, Russell, Winters, Carolyn, Kephart, Julie, Harrison, Michael R., Martinez, Elia, Mundy, Kelly, Halabi, Susan, George, Daniel
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6309626/
https://ncbi.nlm.nih.gov/pubmed/27862097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23277
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares